1352-P: Cardiometabolic Risk Factors Superior to FIB4 in Identifying Adults at Risk for NAFLD with Fibrosis

Introduction 35 or 65 years old. The presence of T2D had a sensitivity of 87% and a specificity of 39% for hepatic fibrosis. Adding obesity to T2D, lowered the sensitivity (76%) but increased specificity to 61%. The presence of T2D, obesity, and hypertension (HTN) together did not change test characteristics. Adding atherogenic dyslipidemia (non-HDL ≥130 mg/dL), however, significantly lowered sensitivity (20%). HOMA-IR and Adipo-IR were sensitive but not specific for hepatic fibrosis. The presence of any combination of ≥3 cardiometabolic risk factors (T2D, obesity, HTN, atherogenic dyslipidemia) had a sensitivity of 86% and specificity of 54% for hepatic fibrosis. The addition of FIB-4 ≥1.3 increased the sensitivity to 97% but decreased specificity to 41%. In comparison, FIB-4 ≥1.3 in those 35-65 years old had a sensitivity of 84% and specificity of 25% for hepatic fibrosis. Conclusion: The presence of ≥3 common cardiometabolic risk factors (T2D, obesity, HTN, atherogenic dyslipidemia) is a simple yet effective clinical screening strategy for NAFLD in all adults with superior specificity compared to FIB-4. Disclosure E. Godinez Leiva: None. A. Sharma: None. S. Kalavalapalli: None. A. Ortiz Rocha: None. E. Valdez Saenz: None. Y. Mohseni: None. N. Cuervo Pardo: None. J.T. Rosenberg: None. J.R. Grajo: None. D. Barb: Speaker's Bureau; Novo Nordisk. Other Relationship; Inventiva Pharma. K. Cusi: Research Support; Echosens, Boehringer-Ingelheim, Quest Diagnostics, Inventiva Pharma, LabCorp, Nordic Bioscience A/S. Consultant; Arrowhead Pharmaceuticals, Inc., AstraZeneca, Boehringer-Ingelheim, Lilly Diabetes, 89bio, Inc., GlaxoSmithKline plc, Novo Nordisk, Siemens Healthcare Diagnostics, Sagimet Biosciences, Terns Pharmaceuticals. Funding National Institutes of Health (R01DK120331)